

Infinium™ Global Diversity Array-8 v1.0

A powerful, cost-effective array with optimized, multi-ethnic, genome-wide content

- Genomic array chosen by the *All of Us* precision medicine initiative to genotype 1 million+ people
- Updated coverage of clinical research variants for a broad range of applications
- Optimized, multiethnic content meets the need for diversity in genomics studies
- High-quality, reproducible data using trusted Infinium chemistry with a scalable workflow

illumina®

Introduction

The 8-sample Infinium Global Diversity Array-8 v1.0 BeadChip (Figure 1) (Table 1) features broad coverage of clinical research variants associated with disease and pharmacogenomics and exome content representing diverse populations (Table 2) (Table 3). The Infinium Global Diversity Array-8 v1.0 BeadChip is built on a high-density single nucleotide polymorphism (SNP) global backbone optimized for crosspopulation imputation coverage of the genome (Figure 2). It enables polygenic risk score development and characterization of genetic architecture in diverse populations.




Figure 1: Infinium Global Diversity Array-8 v1.0 BeadChip is built on the trusted 8-sample Infinium platform.

Table 1: Product information^a

Feature	Description
Species	Human
Total number of markers ^b	1,825,277
Capacity for custom bead types	175,000
Number of samples per BeadChip	8
DNA input requirement	200 ng
Assay chemistry	Infinium LCG
Instrument support	iScan System
Maximum iScan System sample throughput	~1728 samples/week
Scan time per sample	4.4 minutes

a. Approximate values, scan times, and maximum throughput may vary depending on laboratory and system configurations
 b. Variants found on commercial manifest

The combination of a high-density SNP backbone and updated, relevant clinical research variant coverage offers exceptional value per genotype by delivering insights for both discovery and screening applications. The Infinium Global Diversity Array-8 v1.0 BeadChip provides the most cost-effective per variant coverage within the Illumina human array portfolio. It is ideal for precision medicine programs interested in maximizing their return on genotyping investments.




Figure 2: Summary of content—Plotted in the inner pie is the proportion of the array selected for genome-wide coverage, clinical research, and quality control (QC). The outer ring summarizes the weighted reference global allele frequency for unique variants present in the 1000 Genomes Project (1kGP).¹ Variants not in 1kGP are labeled. Counts represent unique variants.

Each Global Diversity Array Kit includes convenient packaging containing BeadChips and reagents for amplifying, fragmenting, hybridizing, labeling, and detecting genetic variants using the high-throughput, streamlined Infinium workflow.

Table 2: High-value content

Content	No. of markers ^a	Research application/note	Content	No. of markers	Research application/note
ACMG ² 59 2016 gene coverage	30,480	Variants with known clinical significance identified from clinical WGS and WES samples	GO ⁹ CVS genes	280,811	Cardiovascular conditions
ACMG 59 all annotations	26,182		Database of Genomic Variants ¹⁰	1,429,631	Genomic structural variation
ACMG 59 pathogenic	9676		eQTLs ¹¹	6392	Genomic loci regulating mRNA expression levels
ACMG 59 likely pathogenic	3288		Fingerprint SNPs ¹²	484	Human identification
ACMG 59 benign	2042		gnomAD ¹³ exome	504,875	WES and WGS results from unrelated individuals from various studies
ACMG 59 likely benign	3788		HLA genes ¹⁴	1040	Disease defense, transplant rejection, and autoimmune disorders
ACMG 59 VUS	5362		Extended MHC ^{14c}	18,352	Disease defense, transplant rejection, and autoimmune disorders
ADME ³ core and extended + CPIC genes	32,528	Drug absorption, distribution, metabolism, and excretion	KIR genes ⁴	156	Autoimmune disorders and disease defense
ADME core and extended + CPIC genes +/- 10 kb	38,246	Includes regulatory regions	Neanderthal SNPs ¹⁵	4143	Neanderthal ancestry and human population migration
AIMs ^b	3055	Ancestry-informative markers	Newborn/carrier screening gene coverage	59,866	Genes associated childhood diseases included in the TruSight [®] Inherited Disease Sequencing Panel ¹⁹
APOE ⁴	89	Cardiovascular disease, Alzheimer's disease, and cognition	NHGRI-EBI GWAS catalog ¹⁶	32,430	Markers from published GWAS
Blood phenotype genes ⁵	2836	Blood phenotypes	PharmGKB ^{17/18} all	4182	Human genetic variation associated with drug responses
ClinVar ⁶ variants	116,609	Relationships among variation, phenotypes, and human health	PharmGKB level 1A	156	
ClinVar pathogenic	25,008		PharmGKB level 1B	7	
ClinVar likely pathogenic	8992		PharmGKB level 2A	26	
ClinVar benign	29,633		PharmGKB level 2B	40	
ClinVar likely benign	19,530		PharmGKB level 3	1694	
ClinVar VUS	24,735		PharmGKB level 4	340	
COSMIC ⁷ genes	971,008	Somatic mutations in cancer	RefSeq ²⁰ 3' UTRs	45,821	3' untranslated regions ^d
CPIC ⁸ all	398	Variants with potential guidelines to optimize drug therapy	RefSeq 5' UTRs	30,723	5' untranslated regions ^d
CPIC-A	257		RefSeq All UTRs	74,386	Untranslated regions ^d
CPIC-A/B	1		RefSeq	1,065,282	All known genes
CPIC-B	16		RefSeq +/- 10 kb	1,196,633	Regulatory regions ^d
CPIC-C	37		RefSeq Promoters	43,735	2 kb upstream to include promoter regions ^d
CPIC-C/D	1		RefSeq Splice Regions	16,762	Variants at splice sites ^d
CPIC-D	63				

- a. The number of markers for each category may be subject to change
- b. Based on internal calculations
- c. Extended MHC is an 8 Mb region
- d. Of all known genes

Abbreviations: ACMG: American College of Medical Genetics; ADME: absorption, distribution, metabolism, and excretion; AIM: ancestry-informative marker; APOE: apolipoprotein E; COSMIC: catalog of somatic mutations in cancer; CPIC: Clinical Pharmacogenetics Implementation Consortium; EBI: European Bioinformatics Institute; eQTL: expression quantitative trait loci; gnomAD: Genome Aggregation Database; GO CVS: gene ontology annotation of the cardiovascular system; GWAS: genome-wide association study; HLA: human leukocyte antigen; KIR: killer cell immunoglobulin-like receptor; MHC: major histocompatibility complex; NHGRI: national human genome research institute; PharmGKB: Pharmacogenomics Knowledge-base; RefSeq: NCBI Reference Sequence Database; UTR: untranslated region; VUS, variant of unknown significance; WES, whole-exome sequencing; WGS, whole-genome sequencing

Chosen by the *All of Us* Research Program

The Infinium Global Diversity Array-8 v1.0 BeadChip is the array chosen by the [All of Us Research Program](#). This program will engage one million or more volunteers living in the United States to contribute their health data over many years to improve health outcomes, fuel the development of new treatments for disease, and catalyze a new era of evidence-based and more precise preventive care and medical treatment. Moreover, one of the program's core values guiding development and implementation is for participants to reflect the rich diversity of the US. The Infinium Global Diversity Array-8 v1.0 BeadChip was built to meet these needs by combining highly optimized multiethnic, genome-wide content with curated clinical research variants.

Table 3: Marker information

Marker category	No. of markers		
Exonic markers ^a	482,865		
Intronic markers ^a	654,467		
Nonsense markers ^b	26,140		
Missense markers ^b	308,978		
Synonymous markers ^b	35,518		
Mitochondrial markers ^b	1354		
Indels ^c	38,694		
Sex chromosomes	X	Y	PAR/homologous
	62,353	6456	5490

a. RefSeq NCBI Reference Sequence Database.²⁰ Accessed April 2021
 b. Compared against the UCSC Genome Browser.⁴ Accessed April 2021
 c. NCBI Genome Reference Consortium, Version GRCh37.²¹ Accessed April 2021
 Abbreviations: indel, insertion/deletion; PAR, pseudoautosomal region

Built through collaboration with leading institutions

The Infinium Global Diversity Array-8 v1.0 BeadChip uses content from the Infinium Multi-Ethnic Global-8 v1.0 BeadChip, a widely used array with adoption by major biobanks. The Infinium Global Diversity Array-8 v1.0 BeadChip contains a robust genome-wide scaffold designed to tag both common and low-frequency variants in global populations (minor allele frequency (MAF) > 1%). This scaffold was designed through collaborations with the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA) and Population Architecture using Genomics and Epidemiology (PAGE).

The Infinium Global Diversity Array-8 v1.0 BeadChip draws from whole-genome sequences not found in the 1000 Genomes Project (1kGP). The array's design leverages more than 1000 whole-genome sequences of African ancestry and populations throughout the Americas, including the US, Caribbean, and Latin and South America.

Exceptional coverage of exonic content

The Infinium Global Diversity Array-8 v1.0 BeadChip includes enhanced tagging in exonic regions and enriched coverage to map genome-wide association study (GWAS) loci with previously identified disease or trait associations with precision. More than 400,000 markers of exome content were gathered from 36,000 individuals of diverse ethnic groups, including African Americans, Hispanics, Pacific Islanders, East Asians, and individuals of mixed ancestry. The Global Diversity Array also features diverse exonic content from the ExAC database,²² including both cross-population and population-specific markers with either functionality or strong evidence for association (Table 4).

Table 4: Exonic coverage across populations

Population ^a	No. of markers ^b
EUR	347,816
EAS	146,700
AMR	273,330
AFR	258,699
SAS	225,330
EUR/EAS/AMR/AFR/SAS	69,351

a. www.internationalgenome.org/category/population; Abbreviations: EUR, European; EAS, East Asian; AMR, Ad Mixed American; AFR, African; SAS, South Asian
 b. Based on gnomAD, gnomad.broadinstitute.org/

Exceptional coverage of variants with known disease associations

The Infinium Global Diversity Array-8 v1.0 BeadChip provides coverage of variants selected from the National Human Genome Research Institute (NHGRI)-GWAS catalog, representing a broad range of phenotypes and disease classifications (Figure 3). This content provides a powerful opportunity for researchers interested in studying diverse populations to test and validate associations previously found in European populations.




Figure 3: NHGRI disease categories—Global Diversity Array clinical research content features markers across a broad range of disease coategories based on the NHGRI database.

Updated and relevant clinical research content

Clinical databases such as ClinVar are constantly evolving as new variants are added and variants change designation to “Pathogenic” or “Likely Pathogenic.” The Infinium Global Diversity Array-8 v1.0 BeadChip provides updated coverage of many of these high-value variants contained within annotated databases. Variants included on the array consist of markers with known disease association based on ClinVar, the Pharmacogenomics Knowledgebase (PharmGKB), and the NHGRI-EBI database (Figure 4). The Infinium Global Diversity Array-8 v1.0 BeadChip also provides imputation-based tagSNPs for HLA alleles, extended MHC region, the KIR gene, and exonic content from the gnomAD database¹³ (Table 2).




Figure 4: Clinical research content—Content was expertly selected from scientifically recognized databases to create a highly informative array for clinical research applications. Variant counts may be subject to change.

Broad spectrum of pharmacogenomics markers

The Infinium Global Diversity Array-8 v1.0 BeadChip provides coverage of pharmacogenomics variants associated with absorption, distribution, metabolism, and excretion (ADME) phenotypes based on PharmGKB¹⁷ and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines⁸ (Figure 5).




Figure 5: Broad spectrum of pharmacogenomics markers—Clinical research content features an extensive list of pharmacogenomics markers selected based on CPIC guidelines and the PharmGKB database.¹⁷ PGx public database variants, variants annotated in PharmGKB, PharmVar, CPIC; Genome-wide PGx coverage, includes markers located in an extended ADME genes or CPIC level A genes including targeted imputation tag SNPs and CPIC level A copy number variation (CNV) tags.

Extensive coverage of diseases

Clinical research content on the Infinium Global Diversity Array-8 v1.0 BeadChip enables validation of disease associations, risk profiling, preemptive screening research, and pharmacogenomics studies. Variant selection includes a range of pathology classifications based on ClinVar and American College of Medical Genetics (ACMG) annotations² (Figure 6A). The BeadChip contains extensive coverage of phenotypes and disease classifications based on ClinVar and the NHGRI-GWAS catalog (Figure 6B).

QC markers for sample tracking

The Infinium Global Diversity Array-8 v1.0 BeadChip includes QC markers for large-scale studies, enabling sample identification, tracking, ancestry determination, and stratification (Figure 7).



Figure 7: QC markers—QC variants on the array enable various capabilities for sample tracking such as sex determination, continental ancestry, human identification, and more.




Figure 6: Broad coverage of disease categories—(A) Variants sorted by range of pathology classifications according to ClinVar American College of Medical Genetics (ACMG) annotations; VUS, variant of unknown significance. (B) Global Diversity Array clinical research content by category within the ClinVar database. Variant counts may be subject to change.

High imputation performance across ancestries

High imputation accuracy provides increased power to support population-scale disease research and population-specific causal variant detection. Leading disease research consortia involved in the development of the Infinium Global Diversity Array-8 v1.0 BeadChip included population-specific and transethnic tag SNPs to maximize imputation performance, enabling more effective association studies in diverse populations (Table 5, Table 6). The Global Diversity Array backbone maximizes the amount of high quality, valuable information that can be extracted per genotyped sample.

Imputation calculation methodology

Imputation performance is measured by simulating Global Diversity Array-8 genotyped variants on 1kGP samples (Table 5, Table 6). A random sample from all 26 global populations of the 1kGP were selected, stratified by super population, and variants on the Global Diversity Array-8 were tested. The remaining 1kGP samples were treated as the reference (1kGP data is already phased using BEAGLE). Minimac3 was used to perform the imputation and imputation quality was measured using the true correlation between all possible imputed genotypes and truth genotypes for all markers from 30x whole-genome sequencing (WGS) data, non-reference concordance (NRC).

Table 5: Imputation accuracy from 1kGP at various MAF thresholds

Population ^b	Imputation accuracy ^a		
	MAF \geq 5%	MAF 1-5%	MAF 0.5-1%
AFR	0.94	0.95	0.94
AMR	0.94	0.92	0.92
EAS	0.90	0.85	0.80
EUR	0.92	0.89	0.86
SAS	0.93	0.91	0.89

a. Compared against Phase 3, version 5 of the 1kGP. internationalgenome.org. Accessed April 2021; Imputed using minimac3

b. internationalgenome.org/category/population

Table 6: Number of markers imputed at $r^2 \geq 0.80$ from 1kGP^a

Population ^b	No. of imputed markers		
	MAF \geq 5%	MAF 1-5%	MAF 0.5-1%
AFR	2,997,752	772,319	2,107,394
AMR	1,995,766	318,771	857,186
EAS	1,702,567	178,995	491,067
EUR	1,926,899	220,590	673,771
SAS	2,502,059	379,634	959,112

a. Compared against Phase 3, version 5 of the 1kGP. internationalgenome.org. Accessed April 2021; Imputed using minimac3

b. internationalgenome.org/category/population

High-throughput workflow

The Infinium Global Diversity Array-8 v1.0 BeadChip uses the proven Infinium 8-sample format that enables laboratories to efficiently scale as needed. For flexible throughput processing, the Infinium assay provides the capability to run up to 1728 samples per week using a single iScan™ System. The Infinium assay provides a three-day workflow that allows users to gather and report data quickly (Figure 8).

For labs interested in quickly scaling or increasing efficiency and operational excellence, the Illumina ArrayLab Consulting Service offers customized solutions.

Trusted, high-quality assay

The Infinium Global Diversity Array-8 v1.0 BeadChip uses trusted Infinium assay chemistry to deliver the same high-quality, reproducible data (Table 7) that Illumina genotyping arrays have provided for over a decade. It is compatible with the Infinium FFPE QC and DNA Restoration Kits,²³ enabling genotyping of formalin-fixed, paraffin-embedded (FFPE) samples. In addition, the high signal-to-noise ratio of the individual genotyping calls from the Infinium assay provides access to genome-wide copy number variant (CNV) calling.




Figure 8: The Infinium workflow provides a rapid three-day workflow with minimal hands-on time.

Table 7: Data performance and spacing

Data performance	Value ^a	Product specification ^b	
Call rate	99.7%	> 99.0% avg	
Reproducibility	99.99%	> 99.90%	
Log R deviation	0.12 ^c	< 0.30 avg ^d	
Spacing			
	Mean	Median	90th% ^c
Spacing (kb)	1.5	0.63	4.0

a. Values are derived from genotyping 2051 HapMap reference samples
 b. Excludes Y chromosome markers for female samples
 c. Based on results from GenTrain sample set
 d. Value expected for typical projects using standard Illumina protocols; Tumor samples and samples prepared by nonstandard protocols are excluded

Summary

Using the iScan System, Infinium assay, and integrated analysis software, the high-density Infinium Global Diversity Array-8 v1.0 BeadChip provides a cost-effective solution for population-scale genetic studies, variant screening, and precision medicine research.

Ordering information

Infinium Global Diversity Array-8 v1.0 BeadChip Kit	Catalog no.
16 samples	20031669
48 samples	20031810
96 samples	20031811
384 samples	20031812
Infinium Global Diversity Array-8+ v1.0 BeadChip Kit ^a	Catalog no.
16 samples	20031813
48 samples	20031814
96 samples	20031815
384 samples	20031816

a. Enabled for custom content

Learn more

Infinium Global Diversity Array-8 v1.0 BeadChip and other Illumina genotyping products, illumina.com/techniques/microarrays.html

References

1. The 1000 Genomes Project. 1000genomes.org. Accessed August 24, 2021.
2. ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing. ncbi.nlm.nih.gov/clinvar/docs/acmg/. Accessed August 4, 2021.
3. PharmaADME Gene List. pharmaadme.org. Accessed August 4, 2021.
4. University of California, Santa Cruz (UCSC) Genome Browser. genome.ucsc.edu. Accessed August 4, 2021.
5. NCBI Reference Sequence Blood Group Antigen Gene Mutation Database. ftp.ncbi.nlm.nih.gov/pub/mhc/rbc/Final%20Archive/. Accessed August 4, 2021.
6. ClinVar Database. ncbi.nlm.nih.gov/clinvar. Accessed August 4, 2021.
7. Catalog of somatic mutations in cancer. cancer.sanger.ac.uk/cosmic. Accessed August 4, 2021.
8. Clinical Pharmacogenetics Implementation Consortium (CPIC). cpicpgx.org. Accessed August 4, 2021.
9. Gene Ontology Consortium. geneontology.org. Accessed August 4, 2021.
10. Database of Genomic Variants. dgv.tcag.ca/dgv/app/home. Accessed August 4, 2021.
11. NCBI database of Genotypes and Phenotypes (dbGaP). preview.ncbi.nlm.nih.gov/gap/eqtl/studies/. Accessed August 4, 2021.
12. The Allele Frequency Database. alfred.med.yale.edu/alfred/sn-pSets.asp. Accessed August 4, 2021.
13. gnomAD, Genome Aggregation Database. gnomad.broadinstitute.org. Accessed August 4, 2021.
14. de Bakker PIW, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. *Nat Genet.* 2006;38:1166–1172.
15. Neanderthal Genome Browser. neandertal.ensemblgenomes.org/index.html. Accessed August 4, 2021.
16. National Human Genome Research Institute. genome.gov/. Accessed August 4, 2021.
17. PharmGKB, The Pharmacogenomics Knowledgebase. pharmgkb.org. Accessed August 4, 2021.
18. PharmGKB, Clinical Annotation Levels of Evidence. pharmgkb.org/page/clinAnnLevels. Accessed August 4, 2021.
19. Illumina. TruSight Inherited Disease Sequencing Panel Data Sheet. illumina.com/content/dam/illumina-marketing/documents/products/datasheets/datasheet_trusight_inherited_disease.pdf. Published 2012. Updated 2016. Accessed August 4, 2021.
20. RefSeq - NCBI Reference Sequence Database. ncbi.nlm.nih.gov/refseq. Accessed August 4, 2021.
21. NCBI Genome Reference Consortium. Version GRCh37. ncbi.nlm.nih.gov/grc/human. Accessed August 4, 2021.
22. Exome Aggregation Consortium (ExAC) Browser. exac.broadinstitute.org. Accessed April 7, 2021.
23. Illumina. Infinium FFPE QC and DNA Restoration Kit Data Sheet. illumina.com/content/dam/illumina-marketing/documents/products/datasheets/datasheet_FFPE_DNA_restoration.pdf. Published 2012. Accessed August 4, 2021.

illumina®

1.800.809.4566 toll-free (US) | +1.858.202.4566 tel
techsupport@illumina.com | www.illumina.com

© 2021 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html.
M-GL-00153 v2.0